Literature DB >> 20212965

Analysis of antibiotic use and misuse in children hospitalized with RSV infection.

L Samson1, C Cooke, N Macdonald.   

Abstract

OBJECTIVE: To determine the extent of, rationale for and acquisition cost of antibiotic use in a cohort of children with lower respiratory tract infection (LRI) secondary to the respiratory syncytial virus (RSV).
DESIGN: Prospective, observational cohort study.
SUBJECTS: Patients younger than two years of age admitted to a tertiary care paediatric hospital with a clinical diagnosis of LRI and positive direct immunoflourescence microscopy and/or viral culture for RSV were eligible. Patients older than two years with underlying cardiac abnormalities, respiratory disease or immunosuppression were also eligible. Patients were enrolled as part of the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of RSV-related LRI.
RESULTS: One hundred and fifty-two patients were enrolled between January 1 and April 30, 1993. Median age was 5.6 months (range 0.2 to 151 months); the male to female ratio was 1.6:1. Morbidity was comparable with that of previously reported cohorts, and no patients died. Sixty-seven (44%) patients received an antibiotic before hospitalization, and ninety-two (60.5%) received at least one antibiotic during hospitalization. Of those receiving antibiotics in hospital, 65 were given oral and 44 intravenous preparations. Reasons for antibiotic prescription during hospitalization were otitis media (37%), 'pneumonia' (31%) and suspected sepsis (9%). Twenty-three per cent had no documented reason. In patients started on intravenous antibiotics, only 32% (14) had the medication discontinued once RSV infection was confirmed. Of the remaining 30 patients, 10 had positive blood (16.6%) or urine (16.6%) cultures, and 15 (50%) had no clearly defined bacterial etiology or rationale documented. Eighty-eight per cent of patients who received ribavirin also received an antibiotic compared with 55% of patients who did not receive ribavirin (P<0.005). The total medication cost of the administered antibiotics was CDN$4,578.16. Eleven adverse events were recorded in children given antibiotics, of which 10 (91%) were in those receiving intravenous preparations.
CONCLUSION: This study demonstrated that a high percentage of children admitted to hospital with LRI secondary to RSV received antibiotics in the absence of a clearly defined bacterial coinfection. Physician education strategies should stress discontinuation of antibiotic therapy once RSV infection is diagnosed. This may diminish the development of resistant bacteria, reduce health care costs and minimize the potential for adverse events associated with inappropriate antibiotic use.

Entities:  

Keywords:  Antibiotics; Children; Lower respiratory tract infection; Respiratory syncytial virus

Year:  1999        PMID: 20212965      PMCID: PMC2828193     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  13 in total

1.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.

Authors:  H W Kim; J O Arrobio; C D Brandt; B C Jeffries; G Pyles; J L Reid; R M Chanock; R H Parrott
Journal:  Am J Epidemiol       Date:  1973-09       Impact factor: 4.897

2.  American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  1993-09       Impact factor: 7.124

Review 3.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

4.  Acute otitis media in children with bronchiolitis.

Authors:  M A Andrade; A Hoberman; J Glustein; J L Paradise; E R Wald
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

5.  Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Authors:  H C Meissner; D R Fulton; J R Groothuis; R L Geggel; G R Marx; V G Hemming; T Hougen; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection.

Authors:  D W Smith; L R Frankel; L H Mathers; A T Tang; R L Ariagno; C G Prober
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

7.  Incidence of acute otitis media associated with group A and B respiratory syncytial virus infections.

Authors:  T Heikkinen; M Waris; O Ruuskanen; A Putto-Laurila; J Mertsola
Journal:  Acta Paediatr       Date:  1995-04       Impact factor: 2.299

8.  Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection.

Authors:  C B Hall; K R Powell; K C Schnabel; C L Gala; P H Pincus
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

9.  Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study.

Authors:  B Friis; P Andersen; E Brenøe; A Hornsleth; A Jensen; F U Knudsen; P A Krasilnikoff; C H Mordhorst; S Nielsen; P Uldall
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 10.  Economic impact of viral respiratory disease in children.

Authors:  H C Meissner
Journal:  J Pediatr       Date:  1994-05       Impact factor: 4.406

View more
  6 in total

1.  Risk factors for disease severity and increased medical resource utilization in respiratory syncytial virus (+) hospitalized children: A descriptive study conducted in four Belgian hospitals.

Authors:  Marijke Proesmans; Annabel Rector; Els Keyaerts; Yannick Vandendijck; Francois Vermeulen; Kate Sauer; Marijke Reynders; Ann Verschelde; Wim Laffut; Kristien Garmyn; Roman Fleischhackl; Jacques Bollekens; Gabriela Ispas
Journal:  PLoS One       Date:  2022-06-06       Impact factor: 3.752

2.  Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.

Authors:  Caroline Amand; Sabine Tong; Alexia Kieffer; Moe H Kyaw
Journal:  BMC Health Serv Res       Date:  2018-04-20       Impact factor: 2.655

3.  Assessing the quality of health care in the management of bronchiolitis in Australian children: a population-based sample survey.

Authors:  Nusrat Homaira; Louise K Wiles; Claire Gardner; Charlotte J Molloy; Gaston Arnolda; Hsuen P Ting; Peter Damian Hibbert; Jeffrey Braithwaite; Adam Jaffe
Journal:  BMJ Qual Saf       Date:  2019-04-02       Impact factor: 7.035

4.  Pediatric Inpatient Antimicrobial Stewardship Program Safely Reduces Antibiotic Use in Patients with Bronchiolitis Caused by Respiratory Syncytial Virus: A Retrospective Chart Review.

Authors:  Jennifer Kalil; Jennifer Bowes; Deepti Reddy; Nick Barrowman; Nicole Le Saux
Journal:  Pediatr Qual Saf       Date:  2019-08-30

5.  Impact of the updating of clinical guidelines for RSV bronchiolitis on the use of diagnostic testing and medications in tertiary hospitals in Colombia.

Authors:  Jefferson Antonio Buendía; Diana Guerrero Patiño
Journal:  Pan Afr Med J       Date:  2022-07-20

6.  Pharyngeal microflora disruption by antibiotics promotes airway hyperresponsiveness after respiratory syncytial virus infection.

Authors:  Ke Ni; Simin Li; Qiuling Xia; Na Zang; Yu Deng; Xiaohong Xie; Zhengxiu Luo; Yan Luo; Lijia Wang; Zhou Fu; Enmei Liu
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.